2-(3,3-difluoropyrrolidin-1-yl)acetamide | 1187325-58-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(3,3-difluoropyrrolidin-1-yl)acetamide
• CAS: 1187325-58-1
• 化学式: C₆H₁₀F₂N₂O
• 分子量: 164.155
• InChiKey: QVIFNKLHVIPVAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  Ethyl (3,3-difluoropyrrolidin-1-yl)acetate 在 氨 作用下， 以 甲醇 为溶剂， 生成 2-(3,3-difluoropyrrolidin-1-yl)acetamide
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN
  [FR] COMPOSÉS DE PYRROLIDINE ET DE PIPÉRIDINE SUBSTITUÉS, LEURS DÉRIVÉS ET PROCÉDÉS DE TRAITEMENT DE LA DOULEUR

  摘要：

  公开号：

  WO2009114950A8

文献信息

• [EN] SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)<br/>[FR] PYRIDONES SUBSTITUES INHIBITEURS DE LA POLY(ADP-RIBOSE) POLYMERASE (PARP)
  申请人：AVENTIS PHARMA INC

  公开号：WO2005097750A1

  公开（公告）日：2005-10-20

  The present invention discloses and claims a series of 2,3,5-substituted pyridone derivatives as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5'-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

  本发明公开并声明了一系列如下定义的2,3,5-取代吡啶酮衍生物。本发明还涉及制备这些化合物的方法。本发明的化合物是多聚腺苷酸二磷酸核糖酶（PARP）的抑制剂，因此在制药剂中特别用于治疗和/或预防各种疾病，包括与中枢神经系统和心血管疾病相关的疾病。
• SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)
  申请人：Weintraub M. Philip

  公开号：US20070032489A1

  公开（公告）日：2007-02-08

  The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R 1 , R 2 , R 3 and R 4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5′-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

  本发明涉及一系列公式I的2,3,5-取代吡啶酮衍生物，其中R，R1，R2，R3和R4如本文所定义。本发明还涉及制备这些化合物的方法。本发明的化合物是聚腺苷酸二磷酸核糖聚合酶（PARP）的抑制剂，因此在治疗和/或预防各种疾病，包括与中枢神经系统和心血管疾病有关的疾病方面，具有药物学上的用途。
• SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN
  申请人：Attardo Giorgio

  公开号：US20110105488A1

  公开（公告）日：2011-05-05

  The present application relates to pyrrolidine, piperidine, and other nitrogen-containing heterocyclic derivatives and the use of these compounds for treating and preventing pam or inflammation. The analgesic compounds demonstrate efficacy in the treatment of neuropathic pain resulting from a variety of conditions such as diabetic neuropathy, HIV infections, and post-herpetic neuralgia.

  本申请涉及吡咯烷，哌啶和其他含氮杂环衍生物及其用于治疗和预防疼痛或炎症的用途。这些镇痛化合物在治疗由各种情况引起的神经病理性疼痛方面表现出有效性，如糖尿病神经病变，HIV感染和带状疱疹后神经痛。
• [EN] PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS<br/>[FR] PYRAZOLOTHIAZOLE CARBOXAMIDES ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE PDGFR
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2022136509A1

  公开（公告）日：2022-06-30

  The disclosure is directed to compounds of formula (I),and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.

  本公开涉及式(I)的化合物及其药学上可接受的盐。还描述了包含式(I)化合物的制药组合物，以及它们的使用和制备方法。
• USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES
  申请人：DelMar Pharmaceuticals, Inc.

  公开号：US20180071244A1

  公开（公告）日：2018-03-15

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of malignancies of the central nervous system in pediatric patients, including glioblastoma multiforme (GBM) high grade glioma, and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N 7 methylation and that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents (e.g. cisplatin) and can possess additive or super-additive effects.